Loading
Journal of Cancer Immunology
ISSN: 2689-968X
Systemic Treatment for Advanced Penile Cancer: Neoadjuvant, Adjuvant and Palliative
Penile cancer is a rare and biologically heterogeneous malignancy in which extensive regional nodal or distant metastatic disease is associated with poor survival. This structured narrative review summarizes current evidence for systemic treatment in the neoadjuvant, adjuvant, first-line palliative, and later-line settings, together with emerging biomarkers and molecularly directed strategies. PubMed/MEDLINE, Embase, Scopus, Web of Science, and ClinicalTrials.gov were searched through 2010 to June 2026.
J Cancer Immunol, 2026, Volume 8, Issue 3, p82-94 | DOI: 10.33696/cancerimmunol.8.128
Patient Preferences for Use of CAR-T Therapy as an Early-Line Treatment in Multiple Myeloma
Purpose: To determine the relative importance of treatment-related attributes on patient preferences for chimeric antigen receptor T-cell (CAR-T) as second-line (2L) multiple myeloma (MM) therapy.
Methods: US patients with relapsed or refractory MM who completed ≥1 line of treatment were recruited via convenience sampling to complete a cross-sectional survey between December 2023 and March 2024.
J Cancer Immunol, 2026, Volume 8, Issue 3, p95-100 | DOI: 10.33696/cancerimmunol.8.129
Bexarotene Enhances Anti-Tumor Efficacy with Cytotoxic Chemotherapy and Increases CD8+ T cell Infiltrate in Breast Tumors
Background: Increased CD8+ T cells in the tumor has shown improved response to therapy and prognosis in breast cancer. Cytotoxic chemotherapies increase immune recognition of the tumor but the effect of chemotherapy on the tumor immune environment is a balance between immune activation and systemic immune suppression. The rexinoic acid receptor agonist bexarotene previously was shown to increase intratumoral CD8+ T cells in TgMMTV-neu transgenic mouse tumors. We therefore determined whether bexarotene could enhance the anti-tumor efficacy of common breast cancer chemotherapies and whether the immune role of bexarotene was contributing to the anti-tumor benefit.
J Cancer Immunol, 2026, Volume 8, Issue 3, p101-111 | DOI: 10.33696/cancerimmunol.8.130
Immune Checkpoint Inhibitor Duration in Advanced Solid Tumors: Should Treatment Stop at Two Years?
Immune checkpoint inhibitors (ICIs) have transformed the natural history of several advanced/metastatic malignancies, producing durable responses that may persist after therapy is stopped. Yet the optimal treatment duration remains uncertain. This article addresses treatment duration only in the advanced/metastatic setting; adjuvant, consolidation, and other curative-intent settings have different therapeutic objectives, relapse risks, and trial-defined durations and should not be extrapolated directly to metastatic disease [1].
J Cancer Immunol, 2026, Volume 8, Issue 3, p121-123 | DOI: 10.33696/cancerimmunol.8.132
Rethinking Initial Treatment in Early-stage Follicular Lymphoma: Time to Align with the Evidence
Follicular lymphoma (FL) is a complex immunological disease with a heterogenous clinical trajectory. It originates in the germinal centers of lymph node follicles, from malignant B-cell lymphocytes that usually harbor the t(14;18) chromosomal translocation, leading to an overexpression of the B-cell lymphoma 2 (Bcl-2) protein [1]. However, BCL2 overexpression alone is insufficient to drive disease development, and FL cells remain highly reliant on interactions with surrounding lymphoma microenvironment (LME) for survival, proliferation, and immune evasion [2–4]. Consequently, the onset and progression of FL are exquisitely dependent on interactions with the LME.
J Cancer Immunol, 2026, Volume 8, Issue 3, p112-120 | DOI: 10.33696/cancerimmunol.8.131
Scientific Archives is a global publisher initiated with the mission of ensuring equal opportunity for accessing science to research community all over the world. Spreading research findings with great relevance to all channels without any barrier is our goal. We want to overcome the challenges of Open Access with ensured quality and transparency.